So far, immune cells that have been engineered to kill cancers, known as CAR T-cells, haven’t worked well against solid ...
Among 16 patients with this difficult-to-treat tumor "with few treatment options," the confirmed overall response rate (ORR) ...
The FDA has granted orphan drug status to the experimental T-cell, or Treg, therapy CK0803, being developed by Cellenkos to ...
Unless a white knight emerges to rescue the business, Galapagos will start a wind-down process that will affect around 365 ...
Oncologists' experience with CGT has increased, with more patients treated and earlier lines of therapy being utilized.
Dr. Matthew Matasar discusses why stem cell transplant is still a standard, life-saving option in blood cancers and how CAR-T ...
Seoul, Seoul / / October 9, 2025 / Lydian Cosmetic Surgery Clinic Key Takeaways Stem cell therapy offers a minimally invasive ...
Novo Nordisk is ending all work in cell therapy, including a Type 1 diabetes program, amid CEO Maziar Mike Doustdar's ...
Liberate Bio’s CAR-M cell therapy almost completely depleted B-cells in a nonhuman primate study, the company said.
Galapagos at the start of the year had planned to split into two businesses, with one resulting entity focused on cell ...
Pharmaceutical Technology on MSN

Galapagos to shutter cell and gene therapy unit

The latest in a trend of companies stepping back from cell and gene therapies amid regulatory uncertainty and manufacturing ...
Shares in Galapagos NV dropped sharply after the Belgian biotech firm said it would wind down its cell-therapy operations, putting paid to plans to sell the business off after no viable offers were ...